ESTEVE acquires Prialt and Quzyttir from TerSera Therapeutics. Discover what this deal signals for non-opioid pain drugs and hospital specialty medicines.
TETON-2 phase 3 data show nebulized treprostinil slows IPF lung decline and cuts clinical worsening risk. Analysis of what the NEJM results mean.
C2N Diagnostics brings its PrecivityAD2 blood test to South Korea through BeauBrain Healthcare. Discover what this means for Alzheimer’s diagnosis.
Insulet's EVOLUTION 2 study shows 68% TIR with no boluses in type 2 diabetes. Analysis of what the FCL data means before the EVOLVE pivotal trial.
Pretzel Therapeutics advances PX578 for POLG disease. Discover how mitochondrial DNA restoration could reshape treatment for rare mitochondrial disorders.
BridgeBio Pharma reports Phase 3 BBP-418 results and prepares FDA filing. Could this become the first therapy for limb-girdle muscular dystrophy?
Could IRX4204 help prevent triple-negative breast cancer? Discover what new RXR agonist research could mean for the future of breast cancer prevention.
PolTREG advances its TREG cell therapy for type 1 diabetes toward EU approval. Learn what this milestone means for autoimmune disease treatment.
FDA clears Toro Neurovascular’s Toro 88 catheter for stroke intervention. Discover how this device could reshape neurovascular access and aspiration thrombectomy.
TIXiMED reports preclinical data showing oral TIX100 may prevent weight regain after GLP-1 therapy. Discover what this could mean for obesity treatment.